A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Recruiting Status:
Recruiting
Age:
18+
A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton’s Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
'